Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.

Abstract: A method is provided for the preparation of anhydrosugar alcohols. The method involves dehydration of a hexitol with a mixed acid of a first acid and second acid, in which the first acid is sulfuric acid and the second acid is at least one sulfur-containing acid or sulfur-containing acid salt selected from the group consisting of p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and aluminum sulfate. Also provided are methods for purification of the resulting product.

Abstract: Method for preparing diamino-dianhydro-dideoxyhexitols, particularly 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol. The invention related to a method for preparing diamino-dianhydro-dideoxyhexitols, particularly preferably 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol.

Abstract: The present disclosure relates to fatty acid derivatives of green tea catechins including epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), epigallocatechin gallate (EGCG) and their epimers (e.g., catechin, catechin gallate, gallocatechin, gallocatechin gallate) or their mixtures and/or green tea extracts.

Abstract: Intermediates of the following formulae for the preparation of lubiprostone:

Abstract: Furfural is produced by contacting a feedstock solution containing C5 sugar and/or C6 sugar with a solid acid catalyst using reactive distillation. Both high yield and high conversion are obtained, without production of insoluble char in the reaction vessel. Degradation of furfural is minimized by its low residence time in contact with the solid acid catalyst. Higher catalyst lifetime can be achieved because the catalyst is continually washed with the refluxing aqueous solution and not sitting in high-boiling byproducts like humins, which are known to be deleterious to catalyst lifetime.

Abstract: The present invention provides a catalyst used for manufacturing an optically active carbonyl compound by selective asymmetric hydrogenation of an ?, ?-unsaturated carbonyl compound, which is insoluble in a reaction mixture, and a method for manufacturing the corresponding optically active carbonyl compound. Particularly, the invention provides a catalyst for obtaining an optically active citronellal useful as a flavor or fragrance, by selective asymmetric hydrogenation of citral, geranial or neral. The invention relates to a catalyst for asymmetric hydrogenation of an ?, ?-unsaturated carbonyl compound, which comprises: a powder of at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table, or a metal-supported substance in which the at least one metal is supported on a support; an optically active cyclic nitrogen-containing compound; and an acid, and also relates to a method for manufacturing an optically active carbonyl compound using the same.

Abstract: The main object of the present invention relates to a novel crystalline form of Fosemprenavir Calcium designated as Form A. Another object of the present invention relates to a process for the preparation of Crystalline Form A of Fosemprenavir Calcium. Yet another object of the present invention relates to crystalline Forma A of Fosemprenavir Calcium characterized by a PXRD diffraction having reflections at about 3.1±0.2, 4.4±0.2, 5.0±0.2, 6.3±0.2, 7.4±0.2, 8.0±0.2, 2?.

Abstract: A compound of formula (I), wherein R1 is hydrogen or a hydroxyl protecting group; and R2 and R3 are same or different and are independently selected from halogen or —O—SO2—X; wherein X is —C1-C4 alkyl; C1-C4 alkyl substituted with one or more halogen; or substituted or unsubstituted phenyl wherein said phenyl substituent is selected from halogen, nitro and C1-C4 alkyl; provided that when R3 is bromine, X is not p-toluoyl; and a process for the preparation thereof.

Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

Abstract: Disclosed are processes for preparing 1,2-cyclohexanediol, and mixtures of 1,2-cyclohexanediol and 1,6-hexanediol, by hydrogenating 1,2,6-hexanetriol.

Abstract: An organic semiconductor represented by the following formula (1). wherein Ar and Ar? are or are not the same as each other and each of them is independently a cyclic compound having a conjugated structure; R and R? are or are not the same as each other and each of them is independently one of a straight chain alkyl group, branched alkyl group, straight chain alkoxy group, branched alkoxy group, hydrogen, and halogen; R? is one of a straight chain alkyl group, branched alkyl group, straight chain alkoxy group, branched alkoxy group, hydrogen, and halogen; x, y, and z are multiples of 0.5, and x?z, y?z; and n is a constant of 1 to 1000.

Abstract: The present invention provides a catalyst complex or ligand, and compositions thereof, for use in a variety of organic reactions having high reactivity and enantioselectivity. The catalyst is a N-heterocyclic carbene having three fused rings with first and second rings being six-membered rings and the third being a five-membered ring. The first ring is fused to the second and has four substituents. The second ring has two nitrogens flanking a carbene atom with one nitrogen bound to a substituent. The carbene atom may optionally be bonded to a metal. The third ring is fused to the second ring and contains two nitrogens. The third ring of the catalyst has a double bond and two substituents on adjacent non-fused carbons. A non-fused nitrogen of the third ring is partially bonded to another substituent. Methods for the synthesis and use of the catalyst embodiments of the present invention are also provided.

Abstract: Disclosed is a method for producing glycidol by decarboxylation of glycerol carbonate. In the method, an ionic liquid catalyst is added for the reaction. According to the method glycidol can be produced in high yield and selectivity. The method enables the production of glycidol in an easy, simple and environmentally friendly way.

Abstract: The present invention relates to a method for dehydrating a carbohydrate-comprising composition.

Abstract: The present invention regards an improved and industrially advantageous process for the preparation of the 2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called “feso chromenyl” and (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, also called “(R)-feso deacyl”, which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine fumarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate “(R)-feso deacyl”, called form B.

Abstract: A process is described for producing crude maleic anhydride from a reactor effluent stream containing maleic anhydride. The reactor effluent stream is contacted with a solvent having a normal boiling point between about 250° C. and about 350° C., solubility of fumaric acid at least about 0.06 wt % at 60° C., solubility of maleic anhydride at least about 10 wt % at 60° C., solubility in water no higher than about 100 mg/L, density different from the density of water by at least about 0.020 g/mL, and water soluble hydrolysis products with molecular weight no higher than the molecular weight of pentanol. The solvent may be non-cyclic, non-aromatic, linear, and/or branched, and may have the general structure R1COOR2COOR3, wherein R1 and R3 are each linear or branched C3 to C5 groups and R2 is a linear or branched C3 to C8 group.

Abstract: Provided are: a method for rapid fluoromethylation, by which a fluoromethyl group can be easily bonded to an aromatic-ring carbon of an aromatic compound with little generation of by-products; and a process for preparation of a PET tracer using the same. The method is characterized by cross-coupling an organoboron compound in which an aromatic ring is bonded to a boron atom with FCX2Br (wherein X is ordinary hydrogen or heavy hydrogen) in a solvent obtained by adding water to an aprotic polar solvent, in the presence of a palladium complex, a phosphine ligand, and a base.

Abstract: A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.

Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Compounds of the invention include those of formula: and pharmacologically acceptable salts thereof where variables Z, Y, M, y, n, R, R4, R5, R1 and R2 are as defined in the specification. M most generally represents a chemical moiety which is in conjugation with the nitrogen of the core beta-lactam ring system of the compound, such that one or more reactive species, e.g., electrophilic or nucleophilic sites are generated on modification of M which is initiated by cleavage of the beta-lactam ring. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition.